SeqLL (SEQL) ROCE % : -152.52% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SeqLL ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. SeqLL's annualized ROCE % for the quarter that ended in Dec. 2023 was -152.52%.

SeqLL ROCE % Historical Data

The historical data trend for SeqLL's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SeqLL ROCE % Chart

SeqLL Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-1,697.04

-88.87

-52.11

-121.97

SeqLL Quarterly Data
	Dec18	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-62.65	-96.00	-86.63	-97.52	-152.52

SeqLL ROCE % Calculation

SeqLL's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-5.544	/	( ( (8.414 - 1.228)	+	(4.436 - 2.531) )	/ 2 )
	=	-5.544	/	( (7.186	+	1.905)	/ 2 )
	=	-5.544	/	4.5455
	=	-121.97 %

SeqLL's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-4.88	/	( ( (5.508 - 1.014)	+	(4.436 - 2.531) )	/ 2 )
	=	-4.88	/	( ( 4.494	+	1.905 )	/ 2 )
	=	-4.88	/	3.1995
	=	-152.52 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

SeqLL (OTCPK:SEQL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

SeqLL ROCE % Related Terms

Thank you for viewing the detailed overview of SeqLL's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

SeqLL (SEQL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SeqLL Inc (OTCPK:SEQL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Federal Street, Billerica, MA, USA, 01821

Website

http://www.seqll.com

SeqLL Inc is an early commercial-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple omics fields. The company leverages its expertise with True Single Molecule Sequencing (tSMS) technology enabling researchers and clinicians to contribute advancements to scientific research and development by accelerating one's understanding of the molecular mechanisms of disease and fundamental biological processes, It enables researchers to identify and synthesize DNA or RNA strands, irrespective of abundance, in a biological sample and is capable of analyzing billions of molecules in parallel.

Executives

Douglas Patrick Miscoll	director	317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
Daniel Robert Jones	officer: President, CEO	317 NEW BOSTON STREET, SUITE 210, WOBURN MA 01801
David Pfeffer	director	464 IVY AVENUE, HAWORTH NJ 07644
Patrice M. Milos	director	317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
Frances P Scally	officer: CHIEF FINANCIAL OFFICER	66 MELANIE LANE, SYOSSET NY 11791
John Whitcomb Kennedy	officer: CFO, Secretary	166 WINN STREET, WOBURN MA 01801